
ASCO 2022 preview webinar: Key trials with high clinical and commercial impact
Join us for a preview ASCO webinar where a panel of experts will share their perspectives on the potentially practice-changing results in breast cancer, novel approaches in Non-Hodgkin Lymphoma and Myelofibrosis, and a series of exciting MOAs in early-stage trials.
Speakers
Ph.D, General Manager, Oncology & Specialty Therapeutics
Related Content
Newsletter

Oncology Newsletter │ May 2022
Key Trials with High Clinical and Commercial Impact at ASCO 2022 and more
Webinar

ASCO 2022 preview webinar: Key trials with high clinical and commercial impact
Join us for a preview ASCO webinar where a panel of experts will share their perspectives on the potentially practice-changing results in breast cancer, novel approaches in Non-Hodgkin Lymphoma and Myelofibrosis, and a series of exciting MOAs in early-stage trials.
Webinar

Immunotherapies are the scientific answer to cancer, how important is marketing?
In this webinar, experts from Cerner Enviza and life science industry will debate the evolving importance marketing and science are playing in the treatment of oncology patients.
Infographic

Evolution of the immune checkpoint inhibitor market landscape in China
Recent regulatory developments and increasing domestic competition in China are now shaping development strategy for global companies
Newsletter

Oncology Newsletter │ July 2022
Immune checkpoint inhibitors - market landscape in China and more
Infographic

Evolution of biomarker trials across the tumor spectrum
Biomarker driven clinical trials have quickly built momentum in oncology. Explore and understand two decades of developmental trends across a variety of tumors.
Newsletter

Oncology Newsletter January 2022
The evolution of biomarker driven clinical development and more
Infographic

The Breadth of PD(L)1 Development in 2021
Development of immuno-oncology drugs has risen dramatically. With 6 PD(L)1 agents now FDA approved, development now extends to multiple tumor types.
Infographic

Pearls of wisdom: Rare Cancer
Investigate how incidence of rare cancers varies across the U.S, EU, Japan and China.
Infographic

Navigating multiple myeloma
A more positive journey for patients with increased survival rates. View the some of the contributing factors over 2004 to 2014.
Infographic

The Oncology Race in Biotech
Many biotechs are looking for their first approval, including those with large clinical programs in the US and EU and ongoing Phase III trials.
White Paper

Immunotherapies are the scientific answer to cancer, but how important is marketing?
This white paper considers the key issues in oncology of: the rise of immuno-oncology brands, what is happening in the mind of the Oncologists, changing paradigm within Oncology and what does this mean for pharma?
Infographic

Precision Medicine: The Next Generation
For too long oncology patients have been treated with a one-size-fits-all treatment plan. The time has come for a more personalized approach.
Infographic

A Periodic Table of Biomarkers
Tumor-agnostic development strategies are gaining momentum as a way to treat solid and hematological tumors characterized by novel and existing biomarkers.
Infographic

The burden of cancer caregiving across the globe
Data from the National Health & Wellness Survey suggests population aging and economic development influence the role of cancer caregivers and the degree of health, productivity, and financial impacts they report.
Infographic

Better testing, better outcomes in Rare Cancer: BRCA mutation and PARP inhibitors
Could increased testing improve outcomes of more patients in rare cancer? And with HRR mutations occurring in multiple tumor types, are there more cancers these drugs can treat?
Infographic

For the record: CAR-T therapy
An overview of CAR-T trials by clinical phase of development for hematological and solid tumors
Infographic

Better testing, better outcomes in Rare Cancer: NTRK fusions
The diverse nature of NTRK fusions present challenges for identification and diagnosis given their rarity and heterogenous patient populations.
Infographic

Hitting the right targets: An overview of current ADC trials
ADCs target tumor cells with toxic chemotherapy payloads. This interactive infographic detailing the extent of pivotal trial activity by developer, tumor type, molecular target, and payload chemotherapy class
Newsletter

Oncology Newsletter │ August 2022
The value of Real-World Evidence in improving rare cancer care and more
Infographic

CAR-T and the growth of cell therapy trials
While CAR-T therapies are the dominant approach globally with development focused in the US and China, other therapy approaches are steadily rising.
Newsletter

Oncology Newsletter │ October 2022
CAR-T therapies have revolutionized cancer care and more
Newsletter

Oncology Newsletter │November 2022
Winning in the early-stage NSCLC immunotherapy landscape and more
Infographic

Head and neck cancer: Unique challenges require a holistic view
Unique challenges face H&N cancer patients, which gives rise to important considerations driving treatments decisions
Infographic

Signposting a path to better treatments
Trends in historical approvals and setbacks across different stages of disease in Esophageal, Pancreatic, Gastric, Hepatocellular, and Colorectal Cancers
Blog

“I kinda feel like a phony”: the emotional complexities of coping with cancer
In this blog, Cerner Enviza’s Search and Social Intelligence team share the online analysis results of diagnosed cancer patients, uncovering their hopes, fears and feelings.
Blog

We need to better understand the emotional impact of cancer
A cancer diagnosis can put a huge psychological burden on patients and their caregivers. Cerner Enviza is collaborating on a research study with the National Cancer Centre Singapore (NCCS) to better understand this issue and help to advance cancer care.
Infographic

How patients with rare cancers are getting ‘doubly hit’
Rare cancers (RC) are a heterogeneous group of conditions that can be associated with psychological and physical impairments. The incidence of RC is less than six cases per 100,000 people/year1 but altogether, RC diseases account for approximately 24% of all cancer cases diagnosed, higher than any single common cancer2–4. Despite advances in treatments and more long-term survivors living with cancer as a chronic illness5 , five-year relative survival rates are still lower for patients with RCs than common cancers (47% vs. 65%)3
White Paper

How to win in the evolving early-stage NSCLC landscape
Strategic considerations to successfully adapt to the rapidly changing NSCLC global market following the introduction of checkpoint inhibitors in resectable disease (non-driver)